RxDoctor Payments Data

Henry Surber, PA

Medical · Zion Crossroads, VANPI 1093104945

Payments from drug & device makers

$3,905in general payments, 2019–2025

Across 201 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$495
  • Novo Nordisk$474
  • Lilly USA, LLC$453
  • AbbVie$384
  • Pfizer$274
  • Abbott$264
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$3,905100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,905 in reported general payments places this provider in the 85th percentile of 632 medical providers in Virginia.

See all medical providers in Virginia

Medicare billing

Part B allowed, 2024
$63,229
Medicare patients
374
Services billed
1,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$27,259
MounjaroTirzepatide14$16,693
PaxlovidNirmatrelvir/Ritonavir13$1,429
Atorvastatin Calcium161$1,360
Albuterol Sulfate HfaAlbuterol Sulfate55$1,289
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,034
Rosuvastatin Calcium92$987
Bupropion XlBupropion Hcl35$869
Losartan Potassium96$735
Escitalopram Oxalate46$684
Pravastatin Sodium56$684
Metoprolol Succinate61$654
Gabapentin80$609
Montelukast Sodium58$595
Omeprazole79$563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$474$27,25921 claims
Lilly USA, LLCMounjaro$453$16,69314 claims
PfizerPaxlovid$274$1,42913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 632 medical providers in Virginia.

Other medical in Zion Crossroads

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →